Supplementary Table 7. Multivariable analysis stratified by income level

Variable*	OR (95% CI)	*P*-value
Subgroup: high income centers only		
Outcome: DRO development		
Rifaximin on admission	1.07 (0.59–1.92)	0.823
Outcome: composite DRO or death		
Rifaximin on admission	1.06 (0.68–1.66)	0.790
MELD-Na	1.04 (1.02–1.06)	<0.001
Subgroup: upper middle-income centers only		
Outcome: DRO development		
Rifaximin on admission	1.18 (0.74–1.85)	0.488
Male sex	0.67 (0.47–0.95)	0.023
HBV etiology	0.50 (0.30–0.80)	0.005
MELD-Na	1.05 (1.02–1.07)	<0.001
Outcome: composite DRO or death		
Rifaximin on admission	1.06 (0.72–0.54)	0.789
Male sex	0.66 (0.49–0.87)	0.004
HBV etiology	0.35 (0.24–0.51)	<0.001
MELD-Na	1.09 (1.07–1.11)	<0.001
Hemoglobin	1.08 (1.02–1.13)	0.006
Prior AKI	1.62 (1.07–2.48)	0.023
Subgroup: low income centers only		
Outcome: DRO development		
Rifaximin on admission	1.04 (0.60–1.81)	0.901
MELD-Na	1.05 (1.02–1.09)	0.002
Outcome: composite DRO or death		
Rifaximin on admission	1.43 (0.93–2.19)	0.101
MELD-Na	1.11 (1.08–1.14)	<0.001
Hemoglobin	0.88 (0.81–0.95)	0.001

AKI, acute kidney injury; CI, confidence interval; DRO, drug-resistant organism; HBV, hepatitis B virus; MELD-Na, Model for end-stage liver disease; OR, odds ratio.